TNF and tuberculosis: Patients receiving TNF-α-targeted therapies have an increased risk of reactivation of a latent Mycobacterium tuberculosis infection (LTBI), and although there are few and discrepant specific reports in psoriatic patients (5), the risk of active tuberculosis (aTB) is, according to a recent meta-analysis, doubled for patients treated with anti-TNF-α (6).